Literature DB >> 1726733

Flunarizine in the treatment of vestibular vertigo: experimental and clinical data.

R Schmidt1, W Oestreich.   

Abstract

Because maintenance antivertiginous treatment with commonly used drugs is only moderately effective, there is still need for new therapeutic concepts in the therapy of vestibular vertigo. The cerebral calcium antagonist flunarizine (Sibelium) revealed positive vestibular effects in experimental animal studies and in healthy volunteers. Clinical trials versus placebo and reference drugs proved flunarizine to be effective in the treatment of vestibular disorders. Somnolence, weight gain, and, in rare cases, extrapyramidal symptoms and depression were discussed as side effects. Further studies on flunarizine's mechanism of action are needed to elucidate whether its clinical effects are indeed due to calcium-entry blockade.

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 1726733

Source DB:  PubMed          Journal:  J Cardiovasc Pharmacol        ISSN: 0160-2446            Impact factor:   3.105


  3 in total

1.  Vestibular disorders in patients with migraine.

Authors:  A Szirmai
Journal:  Eur Arch Otorhinolaryngol       Date:  1997       Impact factor: 2.503

2.  Flunarizine in the prophylaxis of migrainous vertigo: a randomized controlled trial.

Authors:  Anjali Lepcha; Sophia Amalanathan; Ann Mary Augustine; Amit Kumar Tyagi; Achamma Balraj
Journal:  Eur Arch Otorhinolaryngol       Date:  2013-10-29       Impact factor: 2.503

3.  Atypical antipsychotic profile of flunarizine in animal models.

Authors:  Adriano B L Tort; Oscar P Dall'Igna; Ricardo V de Oliveira; Carlos E A Mantese; Paulo Fett; Márcio W S Gomes; Juliana Schuh; Diogo O Souza; Diogo R Lara
Journal:  Psychopharmacology (Berl)       Date:  2004-07-28       Impact factor: 4.530

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.